Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
BACE Inhibitors Worsen Cognition in Patients with Prodromal Alzheimer’s Disease
Key clinical point: Verubecestat and atabecestat fail in clinical trials for preclinical Alzheimer’s disease.
Major finding: BACE inhibitors worsened cognition in patients with prodromal Alzheimer’s disease.
Study details: The two studies randomized patients to varying doses of verubecestat and atabecestat.
Disclosures: Merck & Co. sponsored the verubecestat study. Janssen sponsored the atabecestat study.
Citation:
Egan MF et al. N Engl J Med. 2019 Apr 11;380:1408-20.